Get the Stockscreener App
1.71
8.06%
-0.15
After Hours:
1.71
Nuvation Bio Inc stock is traded at $1.71, with a volume of 6.42M.
It is down -8.06% in the last 24 hours and down -24.34% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$1.86
Open:
$1.85
24h Volume:
6.42M
Relative Volume:
1.48
Market Cap:
$854.06M
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-4.8857
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
-32.41%
1M Performance:
-24.34%
6M Performance:
-39.15%
1Y Performance:
-41.64%
1-Day Range:
$1.71
$1.86
1-Week Range:
$1.57
$2.72
52-Week Range:
$1.54
$3.97
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
1.71 | 854.06M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 114.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 55.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.64B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.55B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus
RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - marketscreener.com
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times
Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects - Investing.com
Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment - TipRanks
Nuvation Bio stock holds steady as FDA approves lung cancer drug - Investing.com Canada
Nuvation Bio price target maintained at $6 by Citizens JMP - Investing.com South Africa
FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer - PharmExec
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
U.S. FDA Approves Nuvation Bio’s Ibtrozi - Contract Pharma
Nuvation Scores First FDA Nod With Oral Lung Cancer Drug - BioSpace
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtro - GuruFocus
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer - PMLiVE
Nuvation Bio stock falls after FDA approves lung cancer drug By Investing.com - Investing.com Canada
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC - The Pharma Letter
Nuvation Bio stock falls after FDA approves lung cancer drug - Investing.com
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi - MSN
Nuvation Bio (NUVB) Gains FDA Approval for Lung Cancer Drug Ibtr - GuruFocus
Nuvation Bio (NUVB) Trading Halted Amidst Anticipated Announceme - GuruFocus
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche - BioPharma Dive
Nuvation Bio’s IBTROZI Receives FDA Approval - TipRanks
Nuvation Set For First Launch With Ibtrozi In Lung Cancer - insights.citeline.com
Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer Drug IBTROZI | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wed - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wedbush | NUVB Stock News - GuruFocus
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib By Investing.com - Investing.com South Africa
US FDA approves Nuvation Bio’s lung cancer therapy - WSAU
US FDA approves Nuvation Bio's rare lung cancer drug - Reuters
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZ - GuruFocus
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval - Benzinga
Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung - GuruFocus
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtrozi | NUVB Stock News - GuruFocus
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib - Investing.com
Nuvation Bio (NUVB) Trading Resumes | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung Cancer | NUVB Stock News - GuruFocus
Nuvation Bio scores first FDA approval for new lung cancer drug - Endpoints News
Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer - GuruFocus
Nuvation kinase inhibitor wins FDA approval in non-small cell lung cancer - TipRanks
Nuvation Bio stock in focus as FDA clears Ibtrozi (NUVB:NYSE) - Seeking Alpha
Nuvation Bio announces FDA approval of Ibtrozi for advanced ROS-1+ NSCLC - TipRanks
FDA Grants Approval to Nuvation Bio's Ibtrozi for Lung Cancer Treatment (NUVB) | NUVB Stock News - GuruFocus
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - The Joplin Globe
Nuvation Bio (NUVB) Shares Surge Following FDA Approval | NUVB Stock News - GuruFocus
US FDA approves Nuvation Bio's lung cancer therapy - TradingView
Nuvation Bio Stock Trading Halted, Pending Material News Release - marketscreener.com
FDA announces apporval of Nuvation Bio’s Ibtrozi for lung cancer - TipRanks
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $925,000 Holdings in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):